Take the 2020 State of the Industry survey

Article

Your opinion matters.

With all that has happened this year, we want to know where you stand and what that means for the state of obstetrics and gynecological practice.

Take the survey in 5 short minutes to help us craft content for your needs and understand what is affecting you most.

Recent Videos
Supreme Court upholds mifepristone access: Implications for women's health | Image Credit: linkedin.com
The significance of the Supreme Court upholding mifepristone access | Image Credit: unchealth.org
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit: uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
Related Content
Contemporary OB/GYN week in review: Pregnancy prevention, postpartum depression, and more | Image Credit: © Aleksey 159 - © Aleksey 159 - stock.adobe.com.

Contemporary OB/GYN week in review: Pregnancy prevention, postpartum depression, and more

Celeste Krewson, Assistant Editor
July 26th 2024
Article

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Read More

Site Logo

How Individually Identifying More HPV Types Enables Better Patient Management and More Precise Care

September 29th 2023
Podcast

Listen

ZY5301 tablet effective for chronic pelvic pain | Image Credit: © valiantsin- stock.adobe.com.

ZY5301 tablet effective for chronic pelvic pain

Celeste Krewson, Assistant Editor
July 25th 2024
Article

These results indicated a significant reduction of CPP from 12 weeks of ZY5301 treatment. Investigators recommended a ZY5301 600 mg/d dose be investigated in a phase 3 trial.

Read More

Site Logo

The Importance of Including Hemoglobinopathies as a Part of Carrier Screening Panels

September 15th 2023
Podcast

Listen

cUTI Roundtable: The latest therapeutic developments

cUTI Roundtable: The latest therapeutic developments

John Parkinson;Joshua Fitch;Morgan Petronelli, Managing Editor
July 24th 2024
Article

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

Read More

FDA approves femlyv as the first orally disintegrating tablet for pregnancy prevention | Image Credit: © wladimir1804 - © wladimir1804 - stock.adobe.com.

FDA approves femlyv as the first orally disintegrating tablet for pregnancy prevention

Celeste Krewson, Assistant Editor
July 24th 2024
Article

Femlyv, containing norethindrone acetate and ethinyl estradiol, offers a new oral contraceptive option for individuals with swallowing difficulties, expanding access and convenience.

Read More

© 2024 MJH Life Sciences

All rights reserved.